Here's the latest wisdom from the wanna-be analyst
Post# of 30018
Quote:
The stock is currently valued at about the right level. It is VERY likely that development of MANF will NOT lead to that much shareholder value because AMBS does not have any money, or currency. Lympro did not pan out. Eltoprazine has no funding and no Principal investigator. MJFF wants more data on Eltoprazine before pulling the trigger.
Ollie commented, "He's never going to make it as a biotech analyst as long as his anal sphincter muscle is squeezing his neck and cutting off oxygen flow to his brain."
– The IRRELEPHANT –
Posting Irrelevant Nonsense on a Message Board Near You